PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients.

Abstract The purpose of this study is to investigate the most suitable first-line approach and the best combination treatment for primary mediastinal large B-cell lymphoma (PMLBCL) as they have been matter of debate for at least two decades.
PMID
Related Publications

18Ffluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study.

MACOP-B and involved-field radiotherapy is an effective and safe therapy for primary mediastinal large B cell lymphoma.

Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B.

Primary mediastinal large B-cell lymphoma with sclerosis: a clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy.

Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.

Authors

Mayor MeshTerms
Keywords

Chemotherapy

MACOP-B

primary mediastinal lymphoma

radiotherapy

rituximab

Journal Title bmc cancer
Publication Year Start




PMID- 28415982
OWN - NLM
STAT- MEDLINE
DA  - 20170418
DCOM- 20170418
LR  - 20170421
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 17
IP  - 1
DP  - 2017 Apr 17
TI  - The treatment of primary mediastinal large B-cell lymphoma: a two decades
      monocentric experience with 98 patients.
PG  - 276
LID - 10.1186/s12885-017-3269-6 [doi]
AB  - BACKGROUND: The purpose of this study is to investigate the most suitable
      first-line approach and the best combination treatment for primary mediastinal
      large B-cell lymphoma (PMLBCL) as they have been matter of debate for at least
      two decades. METHODS: Our single centre experience in the treatment of 98 de novo
      PMLBCL patients over the last 20 years is reviewed. All patients received MACOP-B
      chemotherapy. Thirty-seven received both rituximab and mediastinal radiotherapy; 
      30 were irradiated after chemotherapy, although not receiving rituximab and 20
      received rituximab without radiotherapy consolidation. Eleven patients received
      chemotherapy only. RESULTS: Sixty-one (62.2%) patients achieved a complete
      response after MACOP-B (with or without rituximab); among the 27 (27.6%) partial 
      responders, 21 obtained a complete response after radiotherapy. At the end of
      their scheduled treatment, 82 patients (83.7%) had a complete and 6 a partial
      response (6.1%). Eleven patients relapsed within the first 2 years of follow-up. 
      The 17-year overall survival is 72.0% (15 patients died); progression-free and
      disease-free survival are 67.6% and 88.4%, respectively. A statistically
      significant difference in overall and progression-free survival was noted among
      treatment groups, although no disease-free survival difference was documented.
      CONCLUSIONS: Our data indicate that a third-generation regimen like MACOP-B could
      be considered a suitable first-line treatment. Mediastinal consolidation
      radiotherapy impacts on survival and complete response rates and remains a good
      strategy to convert partial into complete responses. Data suggest that
      radiotherapy may be avoided in patients obtaining a complete response after
      (immuno)chemotherapy, but this requires confirmation with further ad hoc studies.
FAU - Broccoli, Alessandro
AU  - Broccoli A
AD  - Institute of Haematology "L. e A. Seragnoli", University of Bologna, Via
      Massarenti, 9 - 40138, Bologna, Italy. [email protected]
FAU - Casadei, Beatrice
AU  - Casadei B
AD  - Institute of Haematology "L. e A. Seragnoli", University of Bologna, Via
      Massarenti, 9 - 40138, Bologna, Italy.
FAU - Stefoni, Vittorio
AU  - Stefoni V
AD  - Institute of Haematology "L. e A. Seragnoli", University of Bologna, Via
      Massarenti, 9 - 40138, Bologna, Italy.
FAU - Pellegrini, Cinzia
AU  - Pellegrini C
AD  - Institute of Haematology "L. e A. Seragnoli", University of Bologna, Via
      Massarenti, 9 - 40138, Bologna, Italy.
FAU - Quirini, Federica
AU  - Quirini F
AD  - Institute of Haematology "L. e A. Seragnoli", University of Bologna, Via
      Massarenti, 9 - 40138, Bologna, Italy.
FAU - Tonialini, Lorenzo
AU  - Tonialini L
AD  - Institute of Haematology "L. e A. Seragnoli", University of Bologna, Via
      Massarenti, 9 - 40138, Bologna, Italy.
FAU - Morigi, Alice
AU  - Morigi A
AD  - Institute of Haematology "L. e A. Seragnoli", University of Bologna, Via
      Massarenti, 9 - 40138, Bologna, Italy.
FAU - Marangon, Miriam
AU  - Marangon M
AD  - Institute of Haematology "L. e A. Seragnoli", University of Bologna, Via
      Massarenti, 9 - 40138, Bologna, Italy.
FAU - Argnani, Lisa
AU  - Argnani L
AD  - Institute of Haematology "L. e A. Seragnoli", University of Bologna, Via
      Massarenti, 9 - 40138, Bologna, Italy.
FAU - Zinzani, Pier Luigi
AU  - Zinzani PL
AD  - Institute of Haematology "L. e A. Seragnoli", University of Bologna, Via
      Massarenti, 9 - 40138, Bologna, Italy.
LA  - eng
PT  - Journal Article
DEP - 20170417
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 11056-06-7 (Bleomycin)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 5J49Q6B70F (Vincristine)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - Q573I9DVLP (Leucovorin)
RN  - VB0R961HZT (Prednisone)
RN  - YL5FZ2Y5U1 (Methotrexate)
RN  - MACOP-B protocol
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/administration &
      dosage/*therapeutic use
MH  - Bleomycin/administration & dosage
MH  - Cyclophosphamide/administration & dosage
MH  - Doxorubicin/administration & dosage
MH  - Female
MH  - Humans
MH  - Immunotherapy
MH  - Leucovorin/administration & dosage
MH  - Lymphoma, Large B-Cell, Diffuse/drug therapy/pathology/radiotherapy/*therapy
MH  - Male
MH  - Mediastinal Neoplasms/drug therapy/pathology/radiotherapy/*therapy
MH  - Methotrexate/administration & dosage
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prednisone/administration & dosage
MH  - Retrospective Studies
MH  - Rituximab/administration & dosage/therapeutic use
MH  - Vincristine/administration & dosage
MH  - Young Adult
PMC - PMC5392963
OTO - NOTNLM
OT  - Chemotherapy
OT  - MACOP-B
OT  - primary mediastinal lymphoma
OT  - radiotherapy
OT  - rituximab
EDAT- 2017/04/19 06:00
MHDA- 2017/04/19 06:01
CRDT- 2017/04/19 06:00
PHST- 2016/11/04 [received]
PHST- 2017/04/05 [accepted]
AID - 10.1186/s12885-017-3269-6 [doi]
AID - 10.1186/s12885-017-3269-6 [pii]
PST - epublish
SO  - BMC Cancer. 2017 Apr 17;17(1):276. doi: 10.1186/s12885-017-3269-6.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>